Evidence map›Paper›PMID 23578881›Full record

ArticleExperimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie2013

Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta).

Eugenia K Page, Cynthia L Courtney, Prachi Sharma, Jennifer Cheeseman, Joe B Jenkins, Elizabeth Strobert, Stuart J Knechtle

Open access · greenAbstract read
In one paragraph

Article in Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Experimental modeling of desensitization: What have we learned about preventing AMR?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Eugenia K PageEmory Transplant Center, Emory University, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Cynthia L Courtney
Prachi Sharma
Jennifer Cheeseman
Joe B Jenkins
Elizabeth Strobert
Stuart J Knechtle
Emory University · USEmory National Primate Research Center

Funding

YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1M
NCRR NIH HHS P51 RR000165NIAID NIH HHS U19 AI051731
6 · The paper itself

Abstract

Human post-transplant lymphoproliferative disorder (PTLD) is an abnormal lymphoid proliferation that arises in 1-12% of transplant recipients as a consequence of prolonged immunosuppression and Epstein-Barr viral infection (EBV). Nonhuman primates, primarily rhesus macaques (Macaca mulatta), have been used extensively in research models of solid organ transplantation, as the nonhuman primate immune system closely resembles that of the human. Lymphocryptovirus of rhesus monkeys has been characterized and shown to be very similar to EBV in humans in regards to its cellular tropism, host immune response, and ability to stimulate B lymphocyte proliferation and lymphomagenesis. Thus, it appears that the NHP may be an appropriate animal model for EBV-associated lymphoma development in humans. The clinical management of post-transplant nonhuman primates that are receiving multiple immunosuppressive agents can be complicated by the risk of PTLD and other opportunistic infections. We report 3 cases of PTLD in rhesus macaques that illustrate this risk potential in the setting of potent immunosuppressive therapies for solid organ transplantation.

Indexed as

Immunocompromised HostAnimalsDisease Models, AnimalEpstein-Barr Virus InfectionsGraft RejectionHerpesvirus 4, HumanImmunohistochemistryImmunosuppressive AgentsKidney TransplantationLymphoproliferative DisordersMacaca mulattaMaleReverse Transcriptase Polymerase Chain ReactionImmunosuppressive AgentsEpstein–Barr virusNonhuman primatePost-transplant lymphoproliferative disorderRenal transplantation

Identifiers

PMID23578881
PMCPMC3805736
OpenAlexW1994759060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.